Evidence map›Paper›PMID 36400591›Full record

ArticleTransplantation proceedings2022

Analysis of Risk Factors for a Low Immune Response to Messenger RNA COVID-19 Vaccine in Kidney Transplant Recipients and Differences Between Second and Third Dose.

A Panarese, A Canossi, R Fabiani, D Lupi, D Maccarone, P Pace, I Parzanese, V Martinez, L Lancione, V Savino and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation proceedings, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

A PanareseGeneral and Transplant Surgery Department, DISCAB, University of L'Aquila, L'Aquila, Italy. Electronic address: alessandra.panarese@univaq.it.
A CanossiNational Research Council, Institute of Translational Pharmacology (IFT), L'Aquila, Italy.
R FabianiGeneral and Transplant Surgery Department, DISCAB, University of L'Aquila, L'Aquila, Italy.
D LupiGeneral and Transplant Surgery Department, DISCAB, University of L'Aquila, L'Aquila, Italy.
D MaccaroneRegional Transplant Center, San Salvatore Hospital, L'Aquila, Italy.
P PaceRegional Transplant Center, San Salvatore Hospital, L'Aquila, Italy.
I ParzaneseRegional Transplant Center, San Salvatore Hospital, L'Aquila, Italy.
V MartinezRegional Transplant Center, San Salvatore Hospital, L'Aquila, Italy.
L LancioneGeneral and Transplant Surgery Department, San Salvatore Hospital, L'Aquila, Italy.
V SavinoGeneral and Transplant Surgery Department, DISCAB, University of L'Aquila, L'Aquila, Italy.
C CacchioniGeneral and Transplant Surgery Department, DISCAB, University of L'Aquila, L'Aquila, Italy.
C CervelliU.O.C. Regional Center for Immunohematology and Tissue Typing -PO L'Aquila (CRITT), L'Aquila, Italy.
F PapolaU.O.C. Regional Center for Immunohematology and Tissue Typing -PO L'Aquila (CRITT), L'Aquila, Italy.
F PisaniGeneral and Transplant Surgery Department, DISCAB, University of L'Aquila, L'Aquila, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe efficacy of the response to SARS-CoV-2 vaccination in kidney transplant recipients is low. The aim of our study was to evaluate the risk factors correlated with the low antibody response and whether there was an improvement between the second and the third dose.

methodsA prospective study was conducted on 176 kidney transplant recipients who received the second and the third dose of the anti-SARS-CoV-2 mRNA Comirnaty vaccine. We evaluated the seroconversion process after administration of the second and the third dose and assessed a possible correlation with age, time between transplant and vaccination, and type of immunosuppressive therapy.

resultsA total of 98 of the 176 patients (55.7%) responded positively after the inoculation of the second dose and according to the multivariable logistic regression analysis the lack of seroconversion was independently associated with patient age ≥60 (P = .025; odds ratio [OR], 2.094), time since transplant of 1 to 3 months (P = .032; OR, 2.118), and triple therapy (P = .044; OR, 2.327). After the vaccine third dose, the seroconversion increased to 62.5%, and it was negatively influenced by calcineurin inhibitor use (12/21, 57.1% vs 71/78, 91.0%, P = .0006) and triple therapy (13/21, 61.9% vs 72/78, 92.3%, P = .0014). The median of antispike antibody response significantly increased from 18.5 IU/mL after the second dose to 316.9 IU after the third dose (P < .0001).

conclusionsWe demonstrated a correlation between older age and shorter distance from the transplant and triple immunosuppressive therapy with the lack of seroconversion. We noticed a significant improvement in antibody response by a third dose of messenger RNA vaccine.

Indexed as

COVID-19COVID-19 VaccinesKidney TransplantationAntibodies, ViralHumansImmunityProspective StudiesRisk FactorsRNA, MessengerSARS-CoV-2Transplant RecipientsAntibodies, ViralCOVID-19 VaccinesRNA, Messenger

Identifiers

PMID36400591
PMCPMC9595370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.